Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels

References

• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–475.
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990;45:457–461.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio. 2001;2:127–137.
   PubMed Web of Science ®Google Scholar
• Tural D, Akar E, Mutlu H, Kilickap S. P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther. 2014;14:1089–1096.
   PubMed Web of Science ®Google Scholar
• Ludovini V, Gori S, Colozza M, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008;19:883–890.
   PubMed Web of Science ®Google Scholar
• Molina R, Augé JM, Escudero JM, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol. 2010;31:171–180.
   PubMedGoogle Scholar
• Rockberg J, Schwenk JM, Uhlén M. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol Oncol. 2009;3:238–247.
   PubMed Web of Science ®Google Scholar
• Wang J, Willumsen N, Zheng Q, et al. Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. Future Oncol. 2013;9:35–44.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–e79.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. New Engl J Med. 2007;357:39–51.
   PubMed Web of Science ®Google Scholar
• Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. New Engl J Med. 2008;358:1409–1411.
   PubMed Web of Science ®Google Scholar
• Schaller G, Evers K, Papadopoulos S, et al. Current use of HER2 tests. Ann Oncol. 2001;12(1):S97–S100.
   PubMedGoogle Scholar
• Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004;5:105–116.
   PubMedGoogle Scholar
• Schwartz MK, Smith C, Schwartz DC, et al. Monitoring therapy by serum HER-2/neu. Int J Biol Markers. 2000;15:324–329.
   PubMed Web of Science ®Google Scholar
• Mehta RR, McDermott JH, Hieken TJ, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol. 1998;16:2409–2416.
   PubMed Web of Science ®Google Scholar
• Tsé C, Gauchez AS, Jacot W, et al. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012;38:133–142.
   PubMed Web of Science ®Google Scholar
• Kath R, Höftken K, Otte C, et al. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol. 1993;4:585–590.
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Tr. 1998;52:65–77.
   PubMed Web of Science ®Google Scholar
• Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta. 2002;322:11–19.
   PubMed Web of Science ®Google Scholar
• Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15:2518–2525.
   PubMed Web of Science ®Google Scholar
• Fehm T, Gebauer G, Jäger W. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Tr. 2002;75:97–106.
   PubMed Web of Science ®Google Scholar
• Petersen ER, Sørensen PD, Jakobsen EH, et al. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer. Clin Chem Lab Med. 2013;51:1483–1492.
   PubMed Web of Science ®Google Scholar
• Ali SM, Carney WP, Esteva FJ, et al. Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer. Cancer. 2008;113:1294–1301.
   PubMed Web of Science ®Google Scholar
• Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636.
   PubMed Web of Science ®Google Scholar
• Di Gioia D, Dresse M, Mayr D, et al. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014;430:86–91.
   PubMed Web of Science ®Google Scholar
• Sugano K, Ushiama M, Fukutomi T, et al. Combined measurement of the c‐erbb‐2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer. 2000;89(4):329–336.
   PubMed Web of Science ®Google Scholar
• Salvadori B, Pinzani P, Distante V, et al. Comparison of pre-and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. Clin Chem. 2005;51(1):254–256.
   PubMed Web of Science ®Google Scholar
• Kong SY, Kang JH, Kwon Y, et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol. 2006;59(4):373–376.
   PubMed Web of Science ®Google Scholar
• Quaranta M, Daniele A, Coviello M, et al. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori. 2006;92(4):311.
   PubMed Web of Science ®Google Scholar
• Lee SB, Lee JW, Yu JH, et al. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014;14(1):1.
   PubMedGoogle Scholar
• Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005;16(2):234–239.
   PubMed Web of Science ®Google Scholar
• Harmer M, Denoix P, Hamperl H. The TNM-system. Aktuelle Probl Chir. 1970;14:25.
   PubMedGoogle Scholar
• Dittadi R, Zancan M, Perasole A, et al. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers. 2001;16(4):255–261.
   PubMed Web of Science ®Google Scholar
• Kwiecien R, Kopp-Schneider A, Blettner M. Concordance analysis. Dtsch Ärztebl Int. 2011;108:515–521.
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical statistics for medical research. Boca Raton, FL: Chapman & Hall / CRC 1991.
   Google Scholar
• Leary AF, Hanna WM, van de Vijver MJ, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009;27(10):1694–1705.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800–1808.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Cheli C, Fritsche HA, et al. Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy. Breast Cancer Res Tr. 2004;88:S220.
   Web of Science ®Google Scholar
• Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(5):1618–1624.
   PubMed Web of Science ®Google Scholar
• Krüger JM, Thomas M, Korn R, et al. Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy. Am J Pathol. 2013;183(2):336–343.
   PubMed Web of Science ®Google Scholar
• Lam L, McAndrew N, Yee M, et al. Challenges in the clinical utility of the serum test for HER2 ECD. BBA-Rev Cancer. 2012;1826(1):199–208.
   PubMed Web of Science ®Google Scholar
• Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360–363.
   PubMed Web of Science ®Google Scholar
• Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43(6):543–549.
   PubMed Web of Science ®Google Scholar
• Carvajal-Hausdorf DE, Schalper KA, Pusztai L, et al. Measurement of domain-specific HER2 (ERBB2) expression may classify benefit from trastuzumab in breast cancer. J Natl Cancer I. 2015;107(8):djv136.
   PubMedGoogle Scholar